diphenhydramine hydrochloride has been researched along with 2019 Novel Coronavirus Disease in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garcia-Sangenís, A; Gómez-Lumbreras, A; Llor, C; Monfà, R; Moragas, A; Morros, R; Ouchi, D; Pera, H; Pujol, J | 1 |
| Au, SCL | 1 |
| Corsini, GU; Maggio, R | 1 |
| Awasthi, A; Chandra, R; Grover, A; Jain, P; Kumar, N; Kumari, A; Sharma, N; Singh, T; Sood, D | 1 |
1 trial(s) available for diphenhydramine hydrochloride and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Effectiveness of antitussives, anticholinergics, and honey versus usual care in adults with uncomplicated acute bronchitis: a multiarm randomized clinical trial.
Topics: Acute Disease; Adult; Antitussive Agents; Bronchitis; Cholinergic Antagonists; Cough; COVID-19; Dextromethorphan; Honey; Humans; Ipratropium; Pandemics | 2023 |
3 other study(ies) available for diphenhydramine hydrochloride and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Cluster of ocular acute primary angle closure cases and increased antitussive or nasal decongestants usage following the surge in acute COVID-19 infection.
Topics: Acute Disease; Antitussive Agents; COVID-19; Eye Diseases; Face; Humans; Nasal Decongestants | 2023 |
Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection.
Topics: Antitussive Agents; Betacoronavirus; Bromhexine; Coronavirus Infections; COVID-19; Expectorants; Humans; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Protease Inhibitors; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus; Virus Internalization | 2020 |
Antitussive noscapine and antiviral drug conjugates as arsenal against COVID-19: a comprehensive chemoinformatics analysis.
Topics: Antitussive Agents; Antiviral Agents; Cheminformatics; COVID-19; Humans; Molecular Docking Simulation; Noscapine; Protease Inhibitors; SARS-CoV-2 | 2022 |